UCB:EBR
UCB
206,00 €
arrow_upward
+1,98%(+4,00) 1G
15 ott, 17:36:41 GMT+2 · EUR
search
Tutti i simboli
| Simbolo | Prezzo | Cambio | % di cambio |
|---|
insights_autoGenerazione degli insight principali per UCB in corso…
Apertura
202,30 €
Massimo
208,00 €
Minimo
201,70 €
Cap. mercato
38,98 Mld
Vol. medio
241,94K
Volume
399,20K
Dividendo
0,49%
Dividendo trimestrale
0,25 €
Data di stacco dividendo
4 mag 2026
Rapporto P/E
18,22
Max 52 sett.
289,50 €
Min 52 sett.
197,90 €
Utili per azione
11,31 €
Azioni in circolazione
194,51 Mln
N. di dipendenti
9K
Apertura
202,30 €
Massimo
208,00 €
Minimo
201,70 €
Cap. mercato
38,98 Mld
Vol. medio
241,94K
Volume
399,20K
Dividendo
0,49%
Dividendo trimestrale
0,25 €
Data di stacco dividendo
4 mag 2026
Rapporto P/E
18,22
Max 52 sett.
289,50 €
Min 52 sett.
197,90 €
Utili per azione
11,31 €
Azioni in circolazione
194,51 Mln
N. di dipendenti
9K
Articoli giornalistici
Da fonti web e partner giornalistici
ad-hoc-news.de
·
10 ore fa
Barclays keeps EUR 260.00 target for UCB stock, 26.64 percent above price
ad-hoc-news.de
·
15 ore fa
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profilo
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Informazioni su UCB